Recent studies in mouse mammary tumour models show when FAK inhibitor is used in combination with endogenous or exogenous signals that promote activation of T-cell co-stimulatory pathways, e.g., CD80, 4-144BB, and Ox40, anti-tumour immune responses are elevated and were capable of regression in some mouse models33. This evidence concerns the gene CD80 and breast cancer.